文献速递病毒性肝炎艾滋病与性传播感染

格卡瑞韦/哌仑他韦与HIV抗逆转录病毒药物的药物相互作用

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
PubMed 文献 · J Infect Dis · 2020-01-01

该研究通过一系列1期试验评估格卡瑞韦/哌仑他韦与多种HIV抗逆转录病毒药物的相互作用。结果显示,利托那韦增效的HIV蛋白酶抑制剂使格卡瑞韦AUC增加>4倍,阿扎那韦/利托那韦组出现丙氨酸转氨酶升高,依非韦伦可能显著降低格卡瑞韦和哌仑他韦暴露。阿扎那韦为禁忌,不推荐使用增效蛋白酶抑制剂或依非韦伦;其他研究药物无临床显著相互作用。

要点

  • 阿扎那韦与格卡瑞韦/哌仑他韦禁忌合用。
  • 不推荐格卡瑞韦/哌仑他韦与增效蛋白酶抑制剂或依非韦伦联用。
  • 与其他研究的抗逆转录病毒药物无临床显著相互作用。

核心结论

  • 阿扎那韦与格卡瑞韦/哌仑他韦禁忌合用,不推荐使用增效蛋白酶抑制剂或依非韦伦。
  • 与其他研究的抗逆转录病毒药物未观察到临床显著相互作用。

研究设计与样本

  • 一系列1期研究,评估格卡瑞韦和哌仑他韦与多种HIV抗逆转录病毒药物的潜在相互作用。
  • 在单独给药和联合给药时表征抗逆转录病毒药物和DAA的药代动力学,以量化全身药物暴露的变化。

主要发现

  • 利托那韦增效的HIV蛋白酶抑制剂存在时,格卡瑞韦AUC增加>4倍,而哌仑他韦浓度未受显著影响。
  • 仅在与阿扎那韦/利托那韦联合时出现丙氨酸转氨酶升高。
  • 依非韦伦可能显著降低格卡瑞韦和哌仑他韦的暴露。
  • 与格卡瑞韦和哌仑他韦联合给药未导致任何抗逆转录病毒药物暴露的临床显著变化。

关键数值与推荐

  • 格卡瑞韦AUC在利托那韦增效蛋白酶抑制剂存在下增加>4倍。
  • 阿扎那韦与格卡瑞韦/哌仑他韦禁忌合用;不推荐使用增效蛋白酶抑制剂或依非韦伦。

临床怎么用

  • HCV/HIV共感染患者使用格卡瑞韦/哌仑他韦前应审查HIV抗逆转录病毒方案。
  • 避免与阿扎那韦、增效蛋白酶抑制剂或依非韦伦联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of patients coinfected with hepatitis C and human immunodeficiency viruses (HCV; HIV) requires careful consideration of potential drug-drug interactions between HCV direct-acting antiviral agents (DAA) and HIV antiretrovirals. Glecaprevir/pibrentasvir is a fixed-dose combination of an NS3/4A protease inhibitor and an NS5A inhibitor approved for the treatment of chronic HCV genotype 1-6 infection, including patients with HIV coinfection. METHODS: A series of phase 1 studies was conducted to evaluate potential interactions of glecaprevir and pibrentasvir with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir/dolutegravir/lamivudine, raltegravir, rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate. Pharmacokinetics of the antiretrovirals and DAAs were characterized when administered alone and in combination to quantify changes in systemic drug exposure. RESULTS: Glecaprevir area under the curve increased >4-fold in the presence of ritonavir-boosted HIV protease inhibitors, while pibrentasvir concentrations were not significantly affected; elevations in alanine transaminase occurred in combination with atazanavir/ritonavir only. Exposures of glecaprevir and pibrentasvir may be significantly decreased by efavirenz. Coadministration with glecaprevir and pibrentasvir did not result in clinically significant changes in the exposure of any antiretroviral agents. CONCLUSIONS: Atazanavir is contraindicated with glecaprevir/pibrentasvir and use of boosted protease inhibitors or efavirenz is not recommended. No clinically significant interactions were observed with other studied antiretrovirals.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kosloski MP, Oberoi R, Wang S, et al. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals. J Infect Dis. 2020. PMID: 31504702. doi:10.1093/infdis/jiz439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。